Business Wire

Inmarsat Takes Another Leap Forward With ELERA, The Global Network for IoT, Safety and Mission Critical Connectivity

12.8.2021 13:12:00 EEST | Business Wire | Press release

Share

In its second major announcement in two weeks, Inmarsat is today unveiling Inmarsat ELERA; a global narrowband network that is ideally suited to the rapidly evolving world of the Internet of Things (IoT) and for global mobility customers, including aviation, maritime, governments and select enterprises.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210812005417/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Inmarsat Takes Another Leap Forward With ELERA, The Global Network for IoT, Safety and Mission Critical Connectivity (Photo: Business Wire)

“ELERA is perfectly suited to the needs of the connected IoT world,” said Rajeev Suri, CEO, Inmarsat. “Global reach, extraordinary resilience, faster speeds, smaller and lower cost terminals are all part of ensuring that we remain ahead of others in meeting the needs of our customers.”

“ELERA is a further sign of a company with true momentum and one that is delivering new innovations and strong performance,” continued Suri. “I expect that Inmarsat will grow strongly in 2021 compared to the previous year, and that growth will span most of our business units. Our progress was evident in the first half, where we saw strong growth in revenue and EBITDA and robust cash flow. We have sharpened our strategy to focus on driving growth, accelerate decision making, launch new innovations, and are creating a more commercially focused, customer-centric culture.”

ELERA builds on Inmarsat’s #1 position in Mobile Satellite Services (MSS) and will be a springboard for innovation, unlocking, accelerating and scaling pioneering use cases on land, at sea and in the air. Its foundation is Inmarsat’s world class L-band network and incorporates new innovations ranging from higher speeds to smaller, low cost terminals and [the previously announced] Inmarsat-6 satellites, the first of which (I-6 F1) is scheduled to launch before the end of the year.

Coming just 14 days after Inmarsat announced ORCHESTRA, the world’s first network to combine GEO, LEO and 5G into one harmonious global communications solution, ELERA underlines Inmarsat’s strategic focus on the global mobility segment of satellite communications. It is also a signal of a company with momentum, delivering major technological innovations and growth.

The unique capabilities of ELERA, combined with Inmarsat’s superior spectrum and the ideally suited orbital position of its satellite networks, will make it the essential catalyst for new IoT use cases, across everything from autonomous transport and unmanned aerial vehicles (UAV) to industrial and agricultural IoT applications.

ELERA Innovation

ELERA is built on Inmarsat’s market leading L-band network, which already delivers the world’s most reliable and flexible global connectivity service with unique resilience in all conditions and full global redundancy. It supports everything from worldwide maritime and aviation safety services and humanitarian missions to IoT applications across agritech, transportation and utilities, among many others.

The new innovations that the company is investing in to bring to market in the near future include spectrum management technology to deliver L-band speeds up to 1.7Mbps, the smallest footprint, low cost L-band terminal and two new L-band satellites, which are the largest and most sophisticated commercial communication satellites ever created.

The new spectrum management capabilities (known as Carrier Aggregation) being incorporated into the ELERA network will deliver the fastest speeds globally available to L-band customers, far outstripping the capabilities of any other worldwide L-band network.

Live customer trials in commercial aviation are scheduled to start during the course of 2022 and this technology will be rolled out across a range of sector specific applications for Inmarsat’s mobility, government and IoT customers over the coming few years.

ELERA will also see the creation of the smallest footprint, low cost terminal for L-band users, delivering the ideal framework for satcom IoT at scale, with supporting cloud-based management, for vertical sectors such as infrastructure, rail, logistics, mining, agriculture, government, maritime and aviation.

Inmarsat is launching two new satellites to enhance the ELERA network. The I-6 satellites, the first of which is scheduled to launch at the end of 2021, are the largest and most sophisticated commercial communications satellites ever built.

The L-band capacity on each I-6 satellite will be substantially greater than Inmarsat’s 4th generation spacecraft and, among other enhancements, they will deliver 50% more capacity per beam; meaning that much more data can be carried over the same geographical area, in addition to unlimited beam routing flexibility.

ELERA will also deliver a major extension to Inmarsat’s portfolio of voice-enabled devices, bringing new capabilities and innovations to hundreds of thousands of customers. This initiative represents our commitment to voice service innovation and underlines the company’s long-term commitment to the handheld voice services over satellite market.

“ELERA is the exciting vision of how Inmarsat is planning to transform the capabilities offered to IoT and mobility customers for years to come and confirms our long-term commitment to L-band services. We will be sharing further detail on these innovations with our partner community in the coming months and continue our programme of announcements as we achieve major milestones.” said Rajeev Suri, CEO, Inmarsat.

The investments in ELERA are already included in Inmarsat’s current CAPEX plans and guidance.

ENDS

Notes to Editors

ABOUT INMARSAT

Inmarsat is the world leader in global, mobile satellite communications. It owns and operates the world’s most diverse global portfolio of mobile telecommunications satellite networks, and holds a multi-layered, global spectrum portfolio, covering L-band, Ka-band and S-band, enabling unparalleled breadth and diversity in the solutions it provides. Inmarsat’s long-established global distribution network includes not only the world’s leading channel partners but also its own strong direct retail capabilities, enabling end to end customer service assurance.

The company has an unrivalled track record of operating the world’s most reliable global mobile satellite telecommunications networks, sustaining business and mission critical safety and operational applications for more than 40 years. It is also a major driving force behind technological innovation in mobile satellite communications, sustaining its leadership through a substantial investment and a powerful network of technology and manufacturing partners.

Inmarsat operates across a diversified portfolio of sectors with the financial resources to fund its business strategy and holds leading positions in the Maritime, Government, Aviation and Enterprise satcoms markets, operating consistently as a trusted, responsive and high-quality partner to its customers across the globe.

For further information, follow us: Twitter | LinkedIn | Facebook | YouTube | Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media enquiries:
Jonathan Sinnatt / Matthew Knowles
Corporate Communications
Tel: +44 (0)788 960 5272 / +44 (0) 7725 476 507
press@inmarsat.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye